Busca avançada
Ano de início
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Measurement of Calcitonin and Calcitonin Gene-Related Peptide mRNA Refines the Management of Patients with Medullary Thyroid Cancer and May Replace Calcitonin-Stimulation Tests

Texto completo
Mostrar menos -
Camacho, Cleber P. [1] ; Lindsey, Susan C. [1] ; Melo, Maria Clara C. [1] ; Yang, Ji H. [1] ; Germano-Neto, Fausto [1] ; Valente, Flavia de O. F. [1] ; Lima, Thiago R. N. [2] ; Biscolla, Rosa Paula M. [1] ; Vieira, Jose G. H. [1] ; Cerutti, Janete M. [2] ; Dias-da-Silva, Magnus R. [1] ; Maciel, Rui M. B. [1]
Número total de Autores: 12
Afiliação do(s) autor(es):
[1] Univ Fed Sao Paulo, Escola Paulista Med, Dept Med, Lab Mol & Translat Endocrinol, BR-04039032 Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Escola Paulista Med, Dept Genet, BR-04039032 Sao Paulo - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: THYROID; v. 23, n. 3, p. 308-316, MAR 2013.
Citações Web of Science: 12

Background: Serum calcitonin (sCT) is the main tumor marker for medullary thyroid cancer (MTC), but it has certain limitations. Various sCT assays may have important intra-assay or interassay variation and may yield different and sometimes conflicting results. A pentagastrin-or calcium-stimulation calcitonin (CT) test may be desirable in some situations. Alternatively, or in the absence of the stimulation test, mRNA detection offers the advantages of being more comfortable and less invasive; it only requires blood collection and has no side effects. The objective of this study was to investigate the applicability of measuring calcitonin-related polypeptide alpha (CALCA) gene transcripts (CT-CALCA and calcitonin gene-related peptide {[}CGRP]-CALCA) in patients with MTC and in relatives diagnosed with a RET mutation and to test mRNA as an alternative diagnostic tool for the calcitonin-stimulation test. Methods: Twenty-three healthy controls and 26 individuals evaluated for MTC were selected, including patients with sporadic or hereditary MTC and RET mutation-carrying relatives. For molecular analysis, RNA was extracted from peripheral blood, followed by cDNA synthesis using 3.5 mu g of total RNA. Quantitative real-time polymerase chain reaction (RT-qPCR) was performed with SYBR Green and 200nM of each primer for the two specific mRNA targets (CT-CALCA or CGRP-CALCA) and normalized with the ribosomal protein S8 as the reference gene. Results: We detected CALCA transcripts in the blood samples and observed a positive correlation between them (r = 0.946, p < 0.0001). Both mRNAs also correlated with sCT (CT-CALCA, r = 0.713, p < 0.0001; CGRP-CALCA, r = 0.714, p < 0.0001). The relative expression of CT-CALCA and CGRP-CALCA presented higher clinical sensitivity (86.67 and 100, respectively), specificity (97.06 and 97.06), positive predictive value (92.86 and 93.75), and negative predictive value (94.29 and 100), than did sCT (73.33, 82.35, 64.71, and 87.50, respectively). In addition, the CALCA transcript measurement mirrored the response to the pentagastrin test. Conclusion: We demonstrate that the measurement of CALCA gene transcripts in the bloodstream is feasible and may refine the management of patients with MTC and RET mutation-carrying relatives. We propose considering the application of this diagnostic tool as an alternative to the calcitonin-stimulation test. (AU)

Processo FAPESP: 09/11257-7 - Análise do Papel da Arginase II (ARG2) na Patogênese dos Tumores da Tiróide
Beneficiário:Janete Maria Cerutti
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 11/20747-8 - Investigação clínica, bioquímica e molecular da paralisia periódica tirotóxica
Beneficiário:Magnus Régios Dias da Silva
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 10/51547-1 - Carcinoma medular de tiroide hereditario: percepcao e atitude de pacientes, familiares e profissionais de saude sobre questoes bioeticas.
Beneficiário:Rui Monteiro de Barros Maciel
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 06/60402-1 - Carcinoma medular da tiróide: revisitação à clínica, à biologia molecular, à bioquímica e à biologia do desenvolvimento depois dos achados da genética molecular
Beneficiário:Rui Monteiro de Barros Maciel
Linha de fomento: Auxílio à Pesquisa - Temático